DE60026877D1 - Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2,3'übipyridinyl - Google Patents

Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2,3'übipyridinyl

Info

Publication number
DE60026877D1
DE60026877D1 DE60026877T DE60026877T DE60026877D1 DE 60026877 D1 DE60026877 D1 DE 60026877D1 DE 60026877 T DE60026877 T DE 60026877T DE 60026877 T DE60026877 T DE 60026877T DE 60026877 D1 DE60026877 D1 DE 60026877D1
Authority
DE
Germany
Prior art keywords
polymorphic
amorphous
methansulfonylphenyl
bipyridinyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026877T
Other languages
English (en)
Other versions
DE60026877T2 (de
Inventor
Dorothee Clas
Paul O'shea
Chad Dalton
S Crocker
A Mccauley
D Tillyer
Ian Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck Sharp and Dohme LLC
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of DE60026877D1 publication Critical patent/DE60026877D1/de
Application granted granted Critical
Publication of DE60026877T2 publication Critical patent/DE60026877T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE60026877T 1999-11-29 2000-11-27 Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Expired - Lifetime DE60026877T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29
US167922P 1999-11-29
PCT/US2000/032353 WO2001037833A1 (en) 1999-11-29 2000-11-27 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Publications (2)

Publication Number Publication Date
DE60026877D1 true DE60026877D1 (de) 2006-05-11
DE60026877T2 DE60026877T2 (de) 2006-11-23

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026877T Expired - Lifetime DE60026877T2 (de) 1999-11-29 2000-11-27 Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (de)
EP (1) EP1248618B1 (de)
JP (1) JP4425514B2 (de)
AT (1) ATE320809T1 (de)
AU (1) AU776544B2 (de)
CA (1) CA2391650C (de)
DE (1) DE60026877T2 (de)
DK (1) DK1248618T3 (de)
ES (1) ES2259295T3 (de)
PT (1) PT1248618E (de)
WO (1) WO2001037833A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
BRPI1006374A2 (pt) 2009-02-27 2019-09-24 Cadila Healthcare Ltda "processo para a preparação de etoricoxib, composto, processo para a purificação de etoricoxib, forma polimórfica, etoricoxib"
EP2714676B1 (de) * 2011-05-27 2019-04-24 Farma GRS, d.o.o. Verfahren zur herstellung einer polymorphen form i von etoricoxib
WO2013105106A1 (en) 2011-11-03 2013-07-18 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (de) 2011-12-07 2013-06-12 Zentiva, k.s. Neue pharmazeutisch annehmbare Salze und Kokristalle von 5-Chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl und ihre therapeutische Anwendungen
WO2013144977A2 (en) * 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
WO2014041558A2 (en) 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
RS49881B (sr) 1996-07-18 2008-08-07 Merck Frosst Canada Ltd., Supstituisani piridini kao selektivni inhibitori ciklooksigenaze-2
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
RS49945B (sr) 1998-04-24 2008-09-29 Merck & Co.Inc., Postupak za sintetizovanje inhibitora cox-2
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
EP1248618A4 (de) 2003-05-14
ATE320809T1 (de) 2006-04-15
US20030144327A1 (en) 2003-07-31
US6441002B1 (en) 2002-08-27
DK1248618T3 (da) 2006-07-10
EP1248618B1 (de) 2006-03-22
DE60026877T2 (de) 2006-11-23
AU1803101A (en) 2001-06-04
EP1248618A1 (de) 2002-10-16
JP4425514B2 (ja) 2010-03-03
CA2391650A1 (en) 2001-05-31
ES2259295T3 (es) 2006-10-01
CA2391650C (en) 2011-01-25
WO2001037833A1 (en) 2001-05-31
US20020198238A1 (en) 2002-12-26
PT1248618E (pt) 2006-07-31
JP2003514859A (ja) 2003-04-22
AU776544B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
DE60026877D1 (de) Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-2,3'übipyridinyl
AU2002214505A1 (en) New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
ID19602A (id) Piridin tersubstitusi sebagai inhibitor selektif siklooksigenase-2
AR028567A1 (es) Nuevos derivados de fenil-propargileter
AU5996201A (en) Microphysiometer
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
NO20024561D0 (no) Röroppheng med ringromsboring
NO20010619D0 (no) Krystallin base av citalopram
WO2001079169A3 (en) Prostaglandin d2 receptor antagonists
AR028596A1 (es) Nuevos derivados de fenilglicina
ID26310A (id) Produksi kontinyu 1,3-dioksolan-2-ona
NO20023549D0 (no) Fremgangsmåte for rensing av 1,2-dikloretan
NO974921L (no) Kombinasjon av en 5-HT-opptaksinhibitor med en selektiv 5-HT1A antagonist
IS5295A (is) Azetidínýlprópýlpíperidín afleiður, milliefni og notkun sem mótlyf gegn kínínhröðun
NO20021070L (no) Håndtering av boreavfall
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
FI20002903A0 (fi) Bittinopeuden määrittäminen
IS6347A (is) Blanda úr útskiptum bensimídasólum
NO20033196L (no) Fôring av rör
ATE282038T1 (de) Kristallin form ii von cabergolin
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
PT1322592E (pt) Derivados substituidos de 1-aminobutan-3-ol
DE59913178D1 (de) Bohrgestängeverbinder
ID22326A (id) Struktur montasi sarung garpu

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., WHITEHOUSE STATION, N.J., US

Owner name: MERCK FROSST CANADA LTD., KIRKLAND, QUEBEC, CA

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK FROSST CANADA LTD., KIRKLAND, QUEBEC, CA

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1248618

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK FROSST CANADA LTD., MERCK SHARP & DOHME CORP., , US

Effective date: 20121213

Ref document number: 1248618

Country of ref document: EP

Owner name: MERCK FROSST CANADA LTD., CA

Free format text: FORMER OWNER: MERCK FROSST CANADA LTD., MERCK SHARP & DOHME CORP., , US

Effective date: 20121213

R082 Change of representative

Ref document number: 1248618

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213